.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02A_HormonesAndRelatedAgents.L02AE03_Goserelin.Goserelin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L02A_HormonesAndRelatedAgents.L02AE03_Goserelin.Goserelin| name: | Goserelin |
| ATC code: | L02AE03 | route: | subcutaneous |
| n-compartments | 1 |
Goserelin is a synthetic decapeptide analogue of luteinizing hormone-releasing hormone (LHRH, also known as GnRH) used as a gonadotropin-releasing hormone agonist. It causes a reversible suppression of gonadal steroidogenesis and is indicated mainly in the treatment of hormone-sensitive cancers such as prostate cancer in men and breast cancer in premenopausal women, as well as in some cases of endometriosis. Goserelin is approved and widely used today.
Healthy male volunteers, pharmacokinetics after subcutaneous administration of goserelin (standard clinical dosing regimen).
Cheer, SM, et al., & Wagstaff, AJ (2005). Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs 65(18) 2639–2655. DOI:10.2165/00003495-200565180-00011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16392882